Clinical trials: Induction Phase
Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227630
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 8 sites in Belgium, Italy and 2 more
- Volunteers
- 59 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cardiac Toxicity, Leukemia
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cardiac Toxicity, Leukemia, Lymphoma
- Trial name
- T-Cell #4 (NCT01230983)
- Testing
- asparaginase, cytarabine, dexrazoxane hydrochloride
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia, Malnutrition
Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate if enteral docosahexaenoic acid (DHA) administration during the first three months of treatment reduces the deterioration of nutritional status, treatment toxicity and early mortality in…
- Trial name
- DHA-ALL (NCT01051154)
- Testing
- Docosahexaenoic acid (DHA)
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Nulliparous Women With Prolonged Latent Phase
Trial on Early Induction Versus Expectant Management of Nulliparous Women With a Prolonged Latent Phase
The purpose of the study was to compare early induction versus expectant management regarding outcome and experience of delivery in nulliparous women with a prolonged latent phase.
- Trial name
- NCT01863797
- Testing
- Early induction, Expectant mamagement
- Where
- Sweden
- Volunteers
- 138 people
- Sponsor
- Karolinska Institutet
Neuroblastoma
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy.
- Trial name
- NCT05489887
- Testing
- Naxitamab
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 93 people
- Sponsor
- Giselle Sholler
Sarcoma
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Monocentric, phase I study for advanced sarcoma with adoptive immunotherapy with Cytokine-Induced Killer (CIK). In the first part of the study Patient's' peripheral blood will be collected and CIK cell expansion and storage will…
- Trial name
- NCT04802070
- Testing
- Autologous CIK
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Prof. Franca Fagioli
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006258
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 3 sites in United States, Canada
- Sponsor
- Children's Hospital Los Angeles
Cryopyrin-Associated Periodic Syndromes (CAPS)
HL2351 CAPS Phase II Study
This is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).
- Trial name
- NCT02853084
- Testing
- HL2351
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Handok Inc.
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active…
- Trial name
- Ametrine-2 (NCT06588855)
- Testing
- Afimkibart
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 350 people
- Sponsor
- Hoffmann-La Roche
Allergic Conjunctivitis
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat".
- Trial name
- NCT07675811
- Testing
- REGN-2Cat, Freneslerbart, Mevonlerbart
- Where
- United States
- Volunteers
- 570 people
- Sponsor
- Regeneron Pharmaceuticals
Ulcerative Colitis
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative…
- Trial name
- FIGARO UC 301 (NCT03259334)
- Testing
- Ontamalimab
- Where
- 207 sites in United States, Australia and 16 more
- Volunteers
- 380 people
- Sponsor
- Shire
Myelodysplastic Syndromes, Acute Leukemia
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
Multi-site, non-randomized Phase I/II study involving children and adults.
- Trial name
- NCT02752243
- Testing
- CIK-Cells
- Where
- 5 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Peter Bader
Ulcerative Colitis
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis…
- Trial name
- FIGARO UC 302 (NCT03259308)
- Testing
- Ontamalimab
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 279 people
- Sponsor
- Shire
Neuroblastoma
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
The goal of this clinical trial is to to assess the dose level of dinutuximab Beta (DB) when combined with 2 different induction chemotherapy regimens (named GPOH or rapid COJEC) in newly diagnosed high-risk neuroblastoma…
- Trial name
- DBPilot (NCT06485947)
- Testing
- Dinutuximab beta, chemotherapy treatment called GPOH, chemotherapy treatment called rapid COJEC
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Osteosarcoma
Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.
An open-label, multicenter, phase I/II clinical trial to identify the [6R] 5,10-methylenetetrahydrofolate (arfolitixorin) dose with most favorable safety prospect and confirmed ability to mitigate high-dose methotrexate induced…
- Trial name
- NCT01987102
- Testing
- Calcium Folinate, [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
- Where
- 5 sites in Czechia, Hungary and 2 more
- Volunteers
- 18 people
- Sponsor
- Isofol Medical AB
Sleep
Circadian Rhythms and Homeostatic Sleep Drive and Their Effect on Reward and Cognitive Control Systems in Adolescents
Adolescence is a time of heightened reward sensitivity and greater impulsivity. On top of this, many teenagers experience chronic sleep deprivation and misalignment of their circadian rhythms due to biological shifts in their…
- Trial name
- CARRS-P1 (NCT05336084)
- Testing
- Ultradian sleep/wake protocol
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Severe Bronchopulmonary Dysplasia
PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants
This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants.
- Trial name
- NCT03392467
- Testing
- PNEUMOSTEM
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Medipost Co Ltd.
Patient Outcome Assessment, Morbidity
Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)
Surgery still remains the main treatment option for Non-Small Cell Lung Cancer (NSCLC) which is limited within the lung parenchyma and possibly invades the intrapulmonary or hilar nodes.
- Conditions
- Patient Outcome Assessment, Morbidity, Mortality
- Trial name
- SRaIT (NCT04092465)
- Testing
- Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy
- Volunteers
- 42 people
- Sponsor
- AHEPA University Hospital
Non-small Cell Lung Cancer
Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients
Evaluate the efficacy and safety of Monosialoganglioside(GM1) to prevent the neurotoxicity induced by cisplatin
- Trial name
- NCT01882621
- Testing
- Monosialoganglioside(GM1), normal saline
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University